Sinalização PI3K/Akt/mTOR
Os inibidores da sinalização PI3K/Akt/mTOR são compostos que têm como alvo as vias da fosfoinositídeo 3-quinase (PI3K), da quinase Akt e do alvo da rapamicina em mamíferos (mTOR). Essas vias são reguladores críticos do crescimento celular, sobrevivência, metabolismo e autofagia, tornando-os alvos-chave na pesquisa de câncer e distúrbios metabólicos. A inibição dessas vias pode ajudar a controlar o crescimento e a proliferação tumoral, oferecendo estratégias terapêuticas potenciais para vários tipos de câncer e outras doenças caracterizadas por sinalização celular desregulada. Na CymitQuimica, oferecemos uma ampla seleção de inibidores de alta qualidade de PI3K/Akt/mTOR para apoiar sua pesquisa em oncologia, sinalização celular e doenças metabólicas.
Subcategorias de "Sinalização PI3K/Akt/mTOR"
- AMPK(158 produtos)
- ATM/ATR(71 produtos)
- DNA-PK(51 produtos)
- EGFR(572 produtos)
- MELK(7 produtos)
- PDK(9 produtos)
- PI3K(242 produtos)
- S6 Quinase(9 produtos)
- gsk-3(112 produtos)
- mTOR(144 produtos)
Exibir 2 mais subcategorias
Foram encontrados 1038 produtos de "Sinalização PI3K/Akt/mTOR"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
Mevastatin
CAS:<p>Mevastatin (ML236B) is an HMG-CoA reductase inhibitor that was initially isolated from the mold Pythium ultimum.</p>Fórmula:C23H34O5Pureza:99.12%Cor e Forma:White-Yellowish To Yellow Powder Solid PowderPeso molecular:390.51GSK-3 inhibitor 4
CAS:<p>Orally active GSK-3 inhibitor 4 targets GSK-3α/β, CDK2/5 (IC50: 0.45-0.68 μM) and may aid in Alzheimer's research by lowering Tau protein.</p>Fórmula:C22H15F2N5OPureza:99.41%Cor e Forma:SoildPeso molecular:403.38Lapatinib
CAS:<p>Lapatinib (GW572016) is an inhibitor of ErbB2 and EGFR (IC50=9.2/10.8 nM) with oral activity.</p>Fórmula:C29H26ClFN4O4SPureza:99.00% - 99.81%Cor e Forma:PowderPeso molecular:581.06SN32976
CAS:<p>SN32976 is a pan PI3K inhibitor. SN32976 potently inhibited PI3K isoforms and mTOR, displaying preferential activity for PI3Kα and sparing of PI3Kδ.</p>Fórmula:C24H33F2N9O4SPureza:98.06%Cor e Forma:SolidPeso molecular:581.64Panitumumab
CAS:<p>Panitumumab is a fully human IgG2 monoclonal antibody targeting the epidermal growth factor receptor EGFR).</p>Pureza:95% - 98.1% (SDS-PAGE); 99.4% (SEC-HPLC)Cor e Forma:LiquidPeso molecular:147 kDaMargetuximab
CAS:<p>Margetuximab (MGAH-22) is a second generation anti-HER2 monoclonal antibody with anti-tumor activity.</p>Pureza:95.3% (SDS-PAGE); 99.3% (SEC-HPLC) - 95.3% (SDS-PAGE); 99.3% (SEC-HPLC)Cor e Forma:LiquidErlotinib hydrochloride
CAS:<p>Erlotinib hydrochloride (NSC 718781) is an EGFR inhibitor (IC50: 2 nM). It is used for the treatment of non-small cell lung cancer.</p>Fórmula:C22H23N3O4·HClPureza:99.78% - 99.85%Cor e Forma:White Or Off-White PowderPeso molecular:429.9Petosemtamab
CAS:<p>Petosemtamab (MCLA 158), a dual-action monoclonal antibody targets EGFR & LGR5, used in solid tumor research like HNSCC & CRC.</p>Pureza:> 95% - > 95%Cor e Forma:LiquidPeso molecular:145.97 kDaBRD0705
CAS:<p>BRD0705: potent, selective GSK3α inhibitor, oral, IC50: 66 nM, 8x more selective than GSK3β.</p>Fórmula:C20H23N3OPureza:99.01%Cor e Forma:SolidPeso molecular:321.42SAR405 R enantiomer
CAS:<p>SAR405 R enantiomer is the less active enantiomer of SAR405. SAR405 is an inhibitor of PIK3C3/Vps34.</p>Fórmula:C19H21ClF3N5O2Pureza:98.04%Cor e Forma:SolidPeso molecular:443.85Parsaclisib
CAS:<p>Parsaclisib (INCB050465) is a potent and selective inhibitor of PI3Kδ(IC50 of 1 nM at 1 mM ATP)</p>Fórmula:C20H22ClFN6O2Pureza:98.59%Cor e Forma:SolidPeso molecular:432.88AZ7550 hydrochloride
CAS:<p>AZ7550 hydrochloride (AZ7550 hydrochloride ), an active metabolite of AZD9291, inhibits the activity of IGF1R (IC50: 1.6 μM).</p>Fórmula:C27H32ClN7O2Pureza:99.65%Cor e Forma:SolidPeso molecular:522.04LCH-7749944
CAS:<p>LCH-7749944 suppresses human gastric cancer cell growth, induces apoptosis, and inhibits PAK4 with IC50 of 14.93 μM.</p>Fórmula:C20H22N4O2Pureza:99.48%Cor e Forma:SolidPeso molecular:350.41Gefitinib
CAS:<p>Gefitinib (ZD1839) is an EGFR first-generation inhibitor with oral activity that inhibits the EGFR 19 Del and L858R mutations.</p>Fórmula:C22H24ClFN4O3Pureza:99.92% - >99.99%Cor e Forma:Light-Yellow Crystalline PowderPeso molecular:446.9Mutated EGFR-IN-1
CAS:<p>Mutated EGFR-IN-1 (Osimertinib analog) is a useful intermediate for the inhibitors design for mutated EGFR, such as L858R EGFR, Exonl9 deletion activating</p>Fórmula:C25H31N7OPureza:98.91%Cor e Forma:SolidPeso molecular:445.569-ING-41
CAS:<p>9-ING-41 is a glycogen synthase kinase-3 inhibitor.</p>Fórmula:C22H13FN2O5Pureza:99.32%Cor e Forma:SolidPeso molecular:404.35Barecetamab
CAS:<p>Barecetamab (ISU-104) is a humanized monoclonal antibody against tyrosine protein kinase ErbB3 with anticancer activity.</p>Pureza:97.1% (SDS-PAGE); 96.4% (SEC-HPLC) - 97.1% (SDS-PAGE); 96.4% (SEC-HPLC)Cor e Forma:LiquidIndazole
CAS:<p>Indazole, a heterocyclic compound, offers diverse biological activities.</p>Fórmula:C7H6N2Pureza:99.59% - 99.85%Cor e Forma:White Or Beige Crystalline PowderPeso molecular:118.14O-Desmethyl gefitinib
CAS:<p>O-Desmethyl gefitinib is an active EGFR inhibitor (IC50: 36 nM), a metabolite of Gefitinib, formed by CYP2D6.</p>Fórmula:C21H22ClFN4O3Pureza:97.17%Cor e Forma:SolidPeso molecular:432.88Intetumumab
CAS:<p>Intetumumab (CNTO 95) is a fully humanized anti-α(v)-integrin monoclonal antibody that is a radiosensitizer for xenograft tumor-bearing mice.</p>Pureza:97.6% (SDS-PAGE); 97.1% (SEC-HPLC) - 97.6% (SDS-PAGE); 97.1% (SEC-HPLC)Cor e Forma:LiquidPeso molecular:145.6 (kDa)Allitinib
CAS:<p>Allitinib (AST-1306) (AST-1306) has anti-cancer activity，and it is an irreversible EGFR and ErbB2 inhibitor with IC50s of 0.5 and 3 nM, respectively. [1]</p>Fórmula:C24H18ClFN4O2Pureza:99.89% - 99.91%Cor e Forma:SolidPeso molecular:448.88NSC781406
CAS:<p>NSC781406 is a highly effective inhibitor of PI3K and mTOR (IC50: 2 nM for PI3Kα).</p>Fórmula:C29H27F2N5O5S2Pureza:99.58%Cor e Forma:SolidPeso molecular:627.68PI4KIIIbeta-IN-10
CAS:<p>PI4KIIIbeta-IN-10 is a potent inhibitor of PI4KIIIβ (IC50 of 3.6 nM).</p>Fórmula:C22H25N3O5S2Pureza:99.76%Cor e Forma:SolidPeso molecular:475.58Lapatinib Ditosylate
CAS:<p>Lapatinib Ditosylate (Tykerb ditosylate) is an effective EGFR and ErbB2 inhibitor (IC50: 10.8/9.2 nM for EGFR/ErbB2).</p>Fórmula:C29H26ClFN4O4S·2C7H8O3SPureza:99.41%Cor e Forma:Yellow SolidPeso molecular:925.46Gancotamab
CAS:<p>Gancotamab (MM-302) is a polyethylene glycolated liposome targeting HER2 with antitumor activity for the study of advanced HER2-positive breast cancer.</p>Pureza:96.7% (SDS-PAGE); 98.4% (SEC-HPLC) - 96.7% (SDS-PAGE); 98.4% (SEC-HPLC)Cor e Forma:LiquidNV-5138
CAS:<p>NV-5138 is a selective and orally active activator of brain mTORC1, with antidepressant effects.Cost-effective and quality-assured.</p>Fórmula:C7H13F2NO2Pureza:98% - ≥98%Cor e Forma:SolidPeso molecular:181.18Khellin
CAS:<p>Khellin (Methafrone) is a vasodilator that also has bronchodilatory action.</p>Fórmula:C14H12O5Pureza:99.89% - 99.95%Cor e Forma:Light Yellow CrystallinePeso molecular:260.24P110δ-IN-1
CAS:<p>P110δ-IN-1 (PWT-143) is an effective and selective inhibitor of P110δ (IC50: 8.4 nM).</p>Fórmula:C31H40N8O3SPureza:99.75%Cor e Forma:SolidPeso molecular:604.77MELK-IN-1
CAS:<p>MELK-IN-1 (MELK inhibitor 17) is a potent inhibitor of maternal embryonic leucine zipper kinase (MELK),(IC50:3nm;Ki:0.39 nM).</p>Fórmula:C31H33N5O4Pureza:99.84%Cor e Forma:SolidPeso molecular:539.62Cyanoacetohydrazide
CAS:<p>Cyanoacetohydrazide (Cyanoacetic hydrazide) is an anti-TB drug. It has also been used to derive compounds that may have antitumor properties.</p>Fórmula:C3H5N3OPureza:99.78%Cor e Forma:Stout Prisms From Alcohol Slightly Brown PowderPeso molecular:99.09Rociletinib
CAS:<p>Rociletinib (CNX-419) is an orally available small molecule, irreversible inhibitor of epidermal growth factor receptor (EGFR) with potential antineoplastic</p>Fórmula:C27H28F3N7O3Pureza:98.52% - 99.25%Cor e Forma:SolidPeso molecular:555.55Safingol hydrochloride
CAS:<p>Safingol hydrochloride (L-threo-dihydrosphingosine hydrochloride) is a PKC-specific inhibitor that inhibits PKC and PI3k and induces cancer cell death.</p>Fórmula:C18H40ClNO2Pureza:99.39% - 99.71%Cor e Forma:SoildPeso molecular:337.969LTURM34
CAS:<p>LTURM34 is an inhibitor of DNA-PK with IC50 of 34 nM.</p>Fórmula:C24H18N2O3SPureza:99.34%Cor e Forma:SolidPeso molecular:414.48Lapatinib ditosylate monohydrate
CAS:<p>Lapatinib ditosylate monohydrate: a drug for advanced breast cancer; may cause liver issues.</p>Fórmula:C29H26ClFN4O4S·2(C7H8O3S)·H2OPureza:98% - 99.41%Cor e Forma:Colourless To Light-Yellow CrystalPeso molecular:943.47Tenalisib
CAS:<p>Tenalisib (RP6530) (RP6530) is a potent and selective inhibitor of PI3Kδ and PI3Kγ(IC50 values of 25 and 33 nM, respectively.)</p>Fórmula:C23H18FN5O2Pureza:99.71%Cor e Forma:SolidPeso molecular:415.42ICSN3250 HCl
CAS:<p>ICSN3250 HCl is an mTOR inhibitor that specifically targets cancer cells, preventing mTOR activation and leading to cytotoxicity.</p>Fórmula:C31H41ClN4O8Pureza:98.46% - 99.60%Cor e Forma:SoildPeso molecular:633.13MK8722
CAS:<p>MK8722 is an effective and systemic activator of pan-AMPK.</p>Fórmula:C24H20ClN3O4Pureza:98.08% - 99.8800%Cor e Forma:SolidPeso molecular:449.89Pyrotinib dimaleate
CAS:<p>Pyrotinib dimaleate is a selective EGFR/HER2 dual inhibitor, respectively, for the treatment of HER2-positive breast cancer.Cost-effective and quality-assured.</p>Fórmula:C40H39ClN6O11Pureza:97.27% - 99.52%Cor e Forma:SolidPeso molecular:815.22Losatuxizumab
CAS:<p>Losatuxizumab (ABT-806) is an anti-EGFR monoclonal antibody with potential anti-tumor activity for the study of advanced malignant solid tumors.</p>Pureza:97.3% (SDS-PAGE); 95.1% (SEC-HPLC) - 97.3% (SDS-PAGE); 95.1% (SEC-HPLC)Cor e Forma:LiquidErlotinib
CAS:<p>Erlotinib (NSC-718781) is an EGFR inhibitor (IC50: 2 nM). It is used for the treatment of non-small cell lung cancer.</p>Fórmula:C22H23N3O4Pureza:98.19% - 99.98%Cor e Forma:White To Off-White PowderPeso molecular:393.44STL127705
CAS:<p>STL127705 inhibits Ku 70/80 protein & DNA-PKCS kinase, IC50s: 3.5 μM & 2.5 μM.</p>Fórmula:C22H20FN5O4Pureza:99.53% - 99.81%Cor e Forma:SolidPeso molecular:437.42AV-412
CAS:<p>AV-412 (MP412) is an EGFR inhibitor (EGFR, EGFR T790M, EGFR L858R, EGFR L858R/T790M and ErbB2 with IC50s of 0.75, 0.79, 0.5, 2.3, 19 nM).</p>Fórmula:C41H44ClFN6O7S2Pureza:99.85% - 99.92%Cor e Forma:SolidPeso molecular:851.41PI4KIIIbeta-IN-9
CAS:<p>PI4KIIIbeta-IN-9 is a potent inhibitor of PI4KIIIβ(IC50 of 7 nM). .</p>Fórmula:C23H25N3O5S2Pureza:97.18%Cor e Forma:SolidPeso molecular:487.59Rilzabrutinib
CAS:<p>Rilzabrutinib (PRN1008) is a reversible covalent, selective and oral active inhibitor of Bruton’s Tyrosine Kinase (BTK)(IC50 of 1.3 nM).</p>Fórmula:C36H40FN9O3Pureza:98.28% - 99.76%Cor e Forma:SolidPeso molecular:665.76Cromolyn sodium
CAS:<p>Cromolyn sodium (FPL-670) is a chromone complex that acts by inhibiting the release of chemical mediators from sensitized mast cells.</p>Fórmula:C23H14Na2O11Pureza:99.4% - 99.95%Cor e Forma:Colorless Crystals From Ethanol + Ether White Crystalline PowderPeso molecular:512.33PT-1
CAS:<p>PT-1 is an AMPKα1 activator that dose-dependently activates AMPK α1394, α1335, and α2398 and enhances AMPK phosphorylation.</p>Fórmula:C23H16ClN3O6SPureza:99.62%Cor e Forma:SolidPeso molecular:497.91Epertinib hydrochloride
CAS:<p>Epertinib hydrochloride (S-22611 hydrochloride) shows potent antitumor activity.</p>Fórmula:C30H28Cl2FN5O3Pureza:99.14%Cor e Forma:SolidPeso molecular:596.48IPI-3063
CAS:<p>IPI-3063 is an effective and selective inhibitor of PI3K p110δ (IC50: 2.5 ± 1.2 nM).</p>Fórmula:C25H25N7O2Pureza:98.00%Cor e Forma:SolidPeso molecular:455.51KRAS G12D inhibitor 25
CAS:<p>KRAS G12D inhibitor 25 (Compound 148) acts as an inhibitor for KRAS G12C and HSP90α, displaying IC50 values of <0.1 μM and 0.1-1 μM respectively. Additionally, it suppresses the proliferation of MIA PaCa-2 and NCI-H358 cell lines, with EC50 values of <0.1 μM and 0.1-1 μM correspondingly. This compound also promotes the degradation of ERBB2, exhibiting a DC50 of 0.1-1 μM.</p>Fórmula:C56H62ClN11O6Cor e Forma:SolidPeso molecular:1020.62Modotuximab
CAS:<p>Modotuximab (DS 1024) is a humanized antibody targeting EGFR with antitumor activity that accelerates the internalization and degradation of EGFR.</p>Pureza:95.5% (SDS-PAGE); 99.3% (SEC-HPLC) - 95.5% (SDS-PAGE); 99.3% (SEC-HPLC)Cor e Forma:LiquidEGFR kinase inhibitor 2
<p>EGFR kinase inhibitor 2 (compound A-7) is a potent EGFR inhibitor targeting the mutations EGFRL858R/T790M/C797S and EGFRDel19/T790M/C797S. This compound shows potential in addressing acquired resistance in the treatment of non-small cell lung cancer.</p>Fórmula:C39H40N6O5Peso molecular:672.30602EGFR WT/T790M/L858R-IN-1
<p>EGFRWT/T790M/L858R-IN-1 (compound 10d) is a potent inhibitor of EGFR, demonstrating IC50 values of 0.097, 0.280, and 0.051 μM for EGFRWT, EGFRT790M, and EGFRL858R, respectively. This compound can be utilized in cancer research.</p>Fórmula:C26H25Cl3N2O3Peso molecular:518.09308PROTAC EGFR degrader 3
CAS:<p>Potent PROTAC EGFR degrader 3; excellent against H1975/HCC827 cells; lysosome-involved mutant degradation.</p>Fórmula:C60H77N13O5SCor e Forma:SolidPeso molecular:1092.4MS39N
CAS:<p>MS39N (compound 27) serves as the negative control for MS39, capable of binding to EGFR without causing its degradation.</p>Fórmula:C55H71ClFN9O7SPeso molecular:1056.73EGFR-IN-110
<p>EGFR-IN-110 (Compound 6) is a covalent inhibitor of EGFR, demonstrating pIC50 values of 9.2 for the EGFR enzyme and 8.7 for EGFR cells. It exhibits strong efficacy in targeting EGFR and maintains good kinase selectivity.</p>Fórmula:C22H16ClFN4O2Peso molecular:422.09458HER2-IN-20
<p>HER2-IN-20 (compound 32) is a potent and selective inhibitor of HER2WT and HER2YVMA, with IC50 values of 49 and 42 nM, respectively. It holds potential for research in non-small cell lung cancer (NSCLC).</p>Fórmula:C30H27ClFN7O2Peso molecular:571.18988EGFR-IN-93
<p>EGFR-IN-93 (compound 18) is an allosteric inhibitor of the T790M/L858R double mutant EGFR. It is applicable for research in non-small cell lung cancer (NSCLC).</p>Fórmula:C22H18FN3O3Peso molecular:391.13322EGFR/HER2-IN-15
<p>EGFR/HER2-IN-15 is a dihydropyrimidine and an effective inhibitor of EGFR/HER2. It significantly suppresses EGFRwt activity with an IC50 of 37.21 nM and exhibits anticancer properties.</p>Fórmula:C28H29N3O6Peso molecular:503.20564Dacomitinib metabolite M2
CAS:<p>Dacomitinib metabolite M2 is also known as Dacomitinib cysteine conjugate. Dacomitinib inhibits both the wild-type (WT) EGFR and EGFR T790M.</p>Fórmula:C27H32ClFN6O4SCor e Forma:SolidPeso molecular:591.1FDA-Approved Kinase Inhibitor Library
<p>A unique collection of 263 kinase inhibitors/regulators for specific targeting of kinases, ready for high-throughput screening and high-content screening.</p>Cor e Forma:LiquidEGFRvIII peptide (PEPvIII)
CAS:<p>PEPvIII, a peptide sequence from EGFRvIII, was designed to represent a target of glioma and is presented by MHC I/II complexes.</p>Fórmula:C70H111N19O24SPureza:98%Cor e Forma:SolidPeso molecular:1634.81IHMT-PI3Kδ-372 S-isomer
CAS:<p>IHMT-PI3Kδ-372 S-isomer is a potent and selective PI3Kδ inhibitor with an IC50 of 14 nM.</p>Fórmula:C26H23F2N7O2Pureza:99.97%Cor e Forma:SoildPeso molecular:503.5Duvelisib (R enantiomer) hydrochloride
<p>Duvelisib (R enantiomer) hydrochloride (INK1197 R enantiomer HCl) is a PI3K inhibitor.</p>Fórmula:C22H18Cl2N6OPureza:99.88% - >99.99%Cor e Forma:SoildPeso molecular:453.32Pertuzumab
CAS:<p>Pertuzumab (anti-HER2) a humanized monoclonal antibody and the first in the class of agents called the HER2 dimerization inhibitors impairs the ability of HER2</p>Pureza:98.00%Cor e Forma:LiquidPeso molecular:148 kDaEP26
<p>EP26 is an orally active and potent inhibitor of EGFR and PD-L1, with IC50 values of 48.6 nM and 1.77 µM, respectively. It reduces the protein expression of p-EGFR and induces cell cycle arrest at the G0/G1 phase. EP26 shows potential for glioblastoma research.</p>Fórmula:C42H42ClFN4O5Peso molecular:736.28278GSK-3 Inhibitor 5
CAS:<p>4-Cyanophenacyl bromide, a ketone, used in drug-making and organic synthesis, blocks GSK-3.</p>Fórmula:C9H6BrNOPureza:99.58%Cor e Forma:Off-White To Light Yellow Crystalline PowderPeso molecular:224.05SJF 1521
CAS:<p>SJF 1521 is an EGFR degrader belonging to the PROTAC class that selectively degrades EGFR while preserving HER2.</p>Fórmula:C57H61ClFN7O9SPureza:99.20%Cor e Forma:SolidPeso molecular:1074.65Oritinib
CAS:<p>Oritinib (SH-1028) is an inhibitor of EGFR with IC50s of 18, 0.7, 4, 0.1, 1.4 and 0.89 nM for EGFR (wt), EGFR (L858R), EGFR (L861Q), EGFR (L858R/T790M), EGFR (</p>Fórmula:C31H37N7O2Pureza:99.62%Cor e Forma:SoildPeso molecular:539.67BMS-599626
CAS:<p>BMS-599626 (AC480) has been used in trials studying the treatment of Cancer, Metastases, and HER2 or EGFR Expressing Advanced Solid Malignancies.</p>Fórmula:C27H27FN8O3Pureza:98.73%Cor e Forma:SolidPeso molecular:530.55EGFR-TK-IN-5
<p>EGFR-TK-IN-5 (Compound NCE 2) is a thiazolyl pyrazoline derivative with significant inhibitory activity and stability against EGFR. It is applicable in tumor research.</p>Fórmula:C26H20ClFN4OSCor e Forma:SolidPeso molecular:490.98GSK3-IN-1
CAS:<p>GSK3-IN-1 is a GSK3B-glycogen synthase kinase-3 beta inhibitor.</p>Fórmula:C14H10ClN3OSPureza:99.66%Cor e Forma:SolidPeso molecular:303.77PROTAC PI3K/110β degrader-1
CAS:<p>PROTACPI3K/110β degrader-1 (J-9) acts as a PROTAC degrader specifically targeting PI3K/110β.</p>Fórmula:C51H65N9O9SCor e Forma:SolidPeso molecular:980.18PI3Kδ-IN-8
CAS:<p>PI3Kδ-IN-8 is a powerful and specific oral inhibitor of PI3Kδ, exhibiting an IC50 of 3.3 nM.</p>Fórmula:C28H21F2N7OCor e Forma:SolidPeso molecular:509.521Necitumumab
CAS:<p>Necitumumab (IMC-11F8) is a human monoclonal antibody against EGFR, an anti-angiogenic agent used in the treatment of advanced non-small cell lung cancer.</p>Pureza:97.9% (SDS-PAGE); 99.1% (SEC-HPLC) - 97.9% (SDS-PAGE); 99.1% (SEC-HPLC)Cor e Forma:LiquidPeso molecular:145.5 kDamTOR inhibitor 13
CAS:<p>Urea derivative; selective mTOR blocker; IC50: 0.29nM (mTOR), 119nM (PI3Kα).</p>Fórmula:C24H22N6O2SPureza:99.75%Cor e Forma:SolidPeso molecular:458.54N,N-Didesethyl Sunitinib
CAS:<p>N,N-Didesethyl Sunitinib Hydrochloride is a potent AMPK inhibitor with IC50 of 393 nM and 141 nM for AMPKα1 and AMPK2,respectively.</p>Fórmula:C18H19FN4O2Pureza:97.1%Cor e Forma:SoildPeso molecular:342.37MeBIO
CAS:<p>MeBIO is an agonist of aryl hydrocarbon receptor, with IC50 of 44 and 55 μM for GSK-3 and CDK1/CyclinB, respectively. MeBIO does not affect GSK-3β.</p>Fórmula:C17H12BrN3O2Pureza:99.64%Cor e Forma:SolidPeso molecular:370.2Etevritamab
CAS:<p>Etevritamab is a monoclonal antibody that targets CD3E/EGFR.</p>Cor e Forma:LiquidErbB-2-binding peptide
CAS:<p>ErbB-2-binding peptide (HER2-binding peptide), a tumor-targeting peptide, holds potential for cancer research applications [1].</p>Fórmula:C43H60N8O11Cor e Forma:SolidPeso molecular:864.98SOS1/EGFR-IN-2
<p>SOS1/EGFR-IN-2 (Compound 4) functions as a dual inhibitor of SOS1 and EGFR, exhibiting IC50 values of 8.3 and 14.6 nM, respectively. It demonstrates significant antiproliferative effects on cancer cells harboring various KRAS mutations.</p>Fórmula:C25H29F3N4O3Cor e Forma:SolidPeso molecular:490.52BMP agonist 1
<p>BMP Agonist 1 (compound 2 b) is a small-molecule stimulator of bone morphogenic protein (BMP) signaling, crucial for the differentiation of C2C12 cells.</p>Fórmula:C21H16N2O6Cor e Forma:SolidPeso molecular:392.36ARUK2001607
CAS:<p>ARUK2001607 selectively inhibits PI5P4Kγ (Kd=7.1 nM) with high selectivity over 150+ kinases.</p>Fórmula:C14H13N3O2S2Pureza:99.75%Cor e Forma:SoildPeso molecular:319.40(32-Carbonyl)-RMC-5552
CAS:<p>(32-Carbonyl)-RMC-5552, a potent mTOR inhibitor, blocks mTORC1/C2, with pIC50 values >9 for p-P70S6K and p-4E-BP1, and 8~9 for p-AKT1/2/3.</p>Fórmula:C93H134N10O24Cor e Forma:SolidPeso molecular:1776.141EGFR T790M/L858R-IN-6
CAS:<p>EGFR T790M/L858R-IN-6 (compound 53), classified as a pyrimidine compound, serves as an effective inhibitor of EGFR T790M/L858R, demonstrating 90.88% inhibition of enzyme activity at a concentration of 0.05 μM [1].</p>Fórmula:C27H27N7O2Cor e Forma:SolidPeso molecular:481.55Amivantamab (FUT8-KO)
<p>Amivantamab (FUT8-KO) is a humanized dual-specificity antibody targeting EGFR-MET, exhibiting immunotherapeutic anticancer activity. This compound inhibits ligand binding, enhances the internalization and degradation of receptor-antibody complexes, and stimulates macrophage-mediated phagocytosis and natural killer cell cytotoxicity, both of which are Fc-dependent.</p>Fórmula:C13H12O4Cor e Forma:LiquidPeso molecular:232.23MS9449
CAS:<p>MS9449 is a powerful EGFR PROTAC; Kd: 17 nM (WT), 10 nM (L858R); targets mutant EGFRs via UPS and autophagy; hinders NSCLC cell growth.</p>Fórmula:C60H76ClFN10O8SPureza:98%Cor e Forma:SolidPeso molecular:1151.82EGFR-IN-15
CAS:<p>EGFR-IN-15 (compound I-005) is a potent EGFR inhibitor, exhibiting an IC50 value of 4 nM. This compound holds potential for oncological research applications.</p>Fórmula:C24H25BrN6O2Cor e Forma:SolidPeso molecular:509.408mTOR inhibitor WYE-28
CAS:<p>Compound 28 (mTOR inhibitor WYE-28) is a selective inhibitor of mTOR (IC50=0.08 nM). Also inhibits PI3Kα (IC50 6 nM).</p>Fórmula:C30H34N8O5Cor e Forma:SolidPeso molecular:586.653SJF 1528
CAS:<p>Potent EGFR & HER2 degrader; DC50 of 39.2 nM in OVCAR8, 736 nM in HeLa; has lapatinib, VHL ligand; inhibits HER2+ breast cancer (IC50=102 nM for SKBr3).</p>Fórmula:C55H57ClFN7O8SCor e Forma:SolidPeso molecular:1030.61(R)-VX-984
CAS:<p>(R)-VX-984 ((R)-M9831) is the (R)-enantiomer of VX-984. VX-984 is a potent inhibitor of DNA-PK.</p>Fórmula:C23H21D2N7OPureza:98%Cor e Forma:SolidPeso molecular:415.49bpV(pic) (potassium hydrate)
CAS:<p>bpV(pic) (potassium hydrate) can be used in related research in the field of life sciences. Its product number is T35630 and CAS number is 148556-27-8.</p>Fórmula:C6H8K2NO9VCor e Forma:SolidPeso molecular:367.266MS9427 TFA
<p>MS9427 TFA: PROTAC EGFR degrader, Kd 7.1 nM (WT), 4.3 nM (L858R), targets mutant EGFR, inhibits NSCLC cell growth, for cancer research.</p>Fórmula:C50H59ClF4N8O14Cor e Forma:SolidPeso molecular:1107.5PROTAC EGFR degrader 10
CAS:<p>PROTAC EGF Rdegrader 10 (Compound B56) is a PROTAC degrader targeting the epidermal growth factor receptor (EGFR) with a DC50 of less than 100 nM. It binds to CRBN-DDB1 with a Ki of 37 nM and degrades EGFR, focal adhesion kinase (FAK), and RSK1, inhibiting the proliferation of BaF3 wild-type and EGFR mutants with an IC50 of less than 150 nM.</p>Fórmula:C49H65ClN10O7SCor e Forma:SolidPeso molecular:973.62EGFR-IN-43
<p>EGFR-IN-43 (17c) is a potent EGFR inhibitor with ER antagonist action, tamoxifen/endoxifen+gefitinib linkage, and strong anticancer activity.</p>Fórmula:C50H55ClFN5O5Cor e Forma:SolidPeso molecular:860.45HDS 029
CAS:<p>HDS 029 has a wide range of applications in life science related research.</p>Fórmula:C17H11ClFN5OCor e Forma:SolidPeso molecular:355.76mTOR inhibitor 9c
CAS:<p>mTOR inhibitor 9c is a selective mTOR inhibitor with IC50 of 0.7nM and 825nM for mTOR and PI3Kα, respectively.</p>Fórmula:C21H22FN5O2SPureza:99.23%Cor e Forma:SoildPeso molecular:427.5mTOR inhibitor 9e
CAS:<p>mTOR inhibitor 9e is a selective mTOR inhibitor with IC50 of 0.68nM and 1359nM for mTOR and PI3Kα, respectively.</p>Fórmula:C22H23N5O2SPureza:98.84%Cor e Forma:SoildPeso molecular:421.52EGFR-IN-136
<p>EGFR-IN-136 (compound 21v) is a potent inhibitor of EGFR, demonstrating IC50 values of 20.2 nM, 1.2 nM, 2.3 nM, and 12.5 nM for EGFRWT, EGFRLR/TM, EGFR19D/TM/CS, and EGFRLR/TM/CS, respectively. It exhibits antiproliferative and antitumor activities and holds potential for research in non-small cell lung cancer (NSCLC).</p>Fórmula:C30H36N7O4PCor e Forma:SolidPeso molecular:589.625S14161
CAS:<p>S14161 has a wide range of applications in life science related research.</p>Fórmula:C17H14FNO4Cor e Forma:SolidPeso molecular:315.3Lumretuzumab
CAS:<p>Lumretuzumab (RG-7116) is a humanized anti-HER3 monoclonal antibody with antitumor activity.</p>Pureza:95.3% (SDS-PAGE); 96.4% (SEC-HPLC) - 95.3% (SDS-PAGE); 96.4% (SEC-HPLC)Cor e Forma:LiquidPhospho-Glycogen Synthase Peptide-2(substrate)
CAS:<p>Phospho-Glycogen Synthase Peptide-2 is a GSK-3 substrate, useful for serine kinase affinity purification.</p>Fórmula:C123H191N40O48PCor e Forma:SolidPeso molecular:3029.087EGFR-IN-76
CAS:<p>EGFR-IN-76 is a potent EGFR inhibitor.</p>Fórmula:C30H30ClFN6O2Pureza:97.02% - 97.72%Cor e Forma:SolidPeso molecular:561.05RMC-6272
CAS:<p>RMC-6272 (RM-006) is a bi-steric mTORC1 inhibitor with selective potency over mTORC2 and shows greater effects than Rapamycin on TSC2-deficient tumors.</p>Fórmula:C95H141FN6O27SCor e Forma:SolidPeso molecular:1850.25Matuzumab
CAS:<p>Matuzumab (EMD 72000) is a humanized monoclonal antibody targeting EGFR that can be used to study non-small cell lung cancer.</p>Pureza:95%Cor e Forma:LiquidPeso molecular:145.9 kDaGSK251
CAS:<p>GSK251 is a novel, orally bioavailable inhibitor of PI3Kδ, exhibiting high potency and selectivity, with a unique binding mode.</p>Fórmula:C29H37FN6O4SPureza:99.8%Cor e Forma:SolidPeso molecular:584.71PX-13-17OH
CAS:<p>PX-13-17OH has a wide range of applications in life science related research.</p>Fórmula:C29H42N2O8Cor e Forma:SolidPeso molecular:546.65KR-27370
<p>KR-27370 (compound 7f) is an antiviral agent and a selective PI4KIIIβ/PI4KIIIα inhibitor, with IC50 values of 3.1 nM and 15.8 nM, respectively. It exhibits inhibitory activity against human rhinovirus (hRV), Coxsackievirus, and other enteroviruses.</p>Fórmula:C27H27N3O6S2Peso molecular:553.13413Gefitinib N-oxide hydrochloride
<p>Gefitinib N-oxide hydrochloride is an N-oxide of EGFR inhibitor Gefitinib with IC50 of 2-37 nM.</p>Fórmula:C22H24ClFN4O41·5HClCor e Forma:SolidPeso molecular:517.59PI3K-IN-19 hydrochloride
CAS:<p>PI3K-IN-19 hydrochloride (WO2017153220, step 5) acts as a phosphatidylinositol-3-kinase (PI3K) inhibitor.</p>Fórmula:C23H27ClN8O5Cor e Forma:SolidPeso molecular:530.97GSK3β Inhibitor XI
CAS:<p>GSK3β Inhibitor XI has GSK3β inhibitory effect.</p>Fórmula:C18H15N5O3Cor e Forma:SolidPeso molecular:349.35PF-06465603
CAS:<p>PF-06465603 is a metabolite of PF-04691502, a highly potent and selective ATP competitive kinase inhibitor of class 1 PI3Ks and mTOR.</p>Fórmula:C22H25N5O5Cor e Forma:SolidPeso molecular:439.46GSK-3β inhibitor 1
CAS:<p>GSK-3β inhibitor 1 is an inhibitor of GSK-3β( IC50 of 4.9 nM) and demonstrates high antidiabetic efficacy.</p>Fórmula:C14H10N2OPureza:99.40%Cor e Forma:SolidPeso molecular:222.24GSK3-IN-4
CAS:<p>GSK3-IN-4 is a GSK-3 inhibitor with IC50 of 0.101-1 μM of GSK-3α and GSK-3β in Calipe Assay.</p>Fórmula:C18H20N4OPureza:98.33%Cor e Forma:SoildPeso molecular:308.38Zenocutuzumab
CAS:<p>Zenocutuzumab (MCLA-128) is a humanized antibody targeting HER2, used for research on tumors driven by NRG1 gene rearrangement.</p>Pureza:97%Cor e Forma:LiquidJYQ-164
<p>JYQ-164 is a small molecule inhibitor targeting human Parkinson's disease protein 7 (PARK7/DJ-1). It functions by covalently and selectively targeting the critical residue Cys106 of PARK7, exhibiting an IC50 of 21 nM. JYQ-164 demonstrates five times greater inhibitory potency against PARK7 compared to the previously reported inhibitor, JYQ-88. It is applicable for research in Parkinson's disease and cancer.</p>Fórmula:C23H26N6O5S2Peso molecular:530.14061PRMT5/EGFR-IN-1
<p>PRMT5/EGFR-IN-1 (Compound 10p) is an orally active dual inhibitor targeting PRMT5 and EGFR, with IC50 values of 15.47 μM and 19.31 μM, respectively. It demonstrates antiproliferative activity against the A549, MCF7, HeLa, and MDA-MB-231 cell lines. This compound also exhibits favorable pharmacokinetic (PK) and pharmacodynamic (PD) properties in vivo and significantly inhibits the growth of MCF7 orthotopic xenograft tumors.</p>Fórmula:C27H22F6N2O2Peso molecular:520.15855EGFR-IN-95
<p>EGFR-IN-95 is a derivative of 2,4-diaminonicotinamide. It effectively inhibits the activity of EGFRdel19/T790M/C797S and L858R/T790M/C797S.</p>Fórmula:C23H28F2N8O3SPeso molecular:534.19731Multi-target kinase inhibitor 4
<p>Multi-target kinase inhibitor 4 (Compound 2) is a PI3K/DNA-PK inhibitor and a potent chemosensitizer that enhances the number of DNA double-strand breaks induced by Doxorubicin. It serves as an effective multidrug resistance (MDR) inhibitor, demonstrating inhibitory activity against P-glycoprotein (P-gp) mediated drug efflux. Multi-target kinase inhibitor 4 can be encapsulated in PEG-coated lipid nanoparticles.</p>Cor e Forma:Odour SolidEGFR-IN-116
<p>EGFR-IN-116 (compound 14D) is an antineoplastic agent. It exhibits an IC50 value of 0.103 μM for EGFR, 0.069 μM for VEGFR-2, and 19.74 μM for Topo II.</p>Fórmula:C26H22N6O2SPeso molecular:482.1525PROTAC EGFR degrader 11
CAS:<p>PROTAC EGFR degrader 11 (Compound B71) is a PROTAC degrader targeting the epidermal growth factor receptor (EGFR), with a DC50 of less than 100 nM. It binds to CRBN-DDB1 with a Ki of 36 nM. This compound effectively degrades EGFR, focal adhesion kinase (FAK), and RSK1, and inhibits the proliferation of BaF3 wild-type and EGFR mutant cells, exhibiting an IC50 of less than 100 nM.</p>Fórmula:C49H64ClFN10O7SCor e Forma:SolidPeso molecular:991.61ZM 449829
CAS:<p>ZM 449829: Selective JAK3 inhibitor, binds to ATP site. pIC50: 6.8 for JAK3, others < 5.0.</p>Fórmula:C13H10OPureza:98%Cor e Forma:SolidPeso molecular:182.222EGFR-IN-128
<p>EGFR-IN-128 (compound 28) is a potent and selective molecule targeting wild-type EGFREx20Ins, demonstrating therapeutic efficacy across various human xenograft models and capable of penetrating the blood-brain barrier in preclinical species.</p>Fórmula:C27H20N4OCor e Forma:SolidPeso molecular:416.47Kinase Inhibitor Library
<p>A unique collection of 2720 kinase inhibitors/regulators for high throughput screening and high content screening for drug discovery in kinase related diseases;</p>Cor e Forma:Odour SolidCN009543V
CAS:<p>CN009543V is an enhancer of tyrosine phosphorylation of EGFR via downstream signaling pathways.</p>Fórmula:C12H12N4O6SCor e Forma:SolidPeso molecular:340.31DNA Damage & Repair Compound Library
<p>A unique collection of xnum DNA Damage &amp; Repair related compounds for high throughput screening (HTS) and high content screening (HCS);</p>Cor e Forma:Odour SolidZLN 024 hydrochloride
CAS:<p>ZLN 024 hydrochloride is an AMPK allosteric activator and stimulates the inactive α1 subunit truncations α1 (1-394) and α1 (1-335) but not α1 (1-312).</p>Fórmula:C13H14BrClN2OSPureza:98.541%Cor e Forma:SolidPeso molecular:361.68HER2-IN-13
CAS:<p>HER2-IN-13 (Compound 33) serves as an effective HER2 inhibitor, exhibiting an IC50 value of 8 nM, and additionally demonstrates inhibition of wt-EGFR with an</p>Fórmula:C26H23ClF2N8O3Cor e Forma:SolidPeso molecular:568.96ALKBH1-IN-3 prodrug
<p>ALKBH1-IN-4 prodrug (Compound 29E) is a prodrug of an inhibitor targeting the DNA N6-methyladenine demethylase enzyme ALKBH1. It works by significantly increasing the cellular abundance of 6mA and enhancing the AMPK signaling pathway, which suppresses the vitality of gastric cancer cells. ALKBH1-IN-4 prodrug displays excellent cellular activity and favorable metabolic exposure in vivo, making it a promising candidate for research in gastric cancer-related areas.</p>Cor e Forma:Odour SolidPI3Kδ-IN-9
CAS:<p>PI3Kδ-IN-9 is a selective PI3Kδ inhibitor with an IC 50 value of 3.8 nM.</p>Fórmula:C24H26FN9OCor e Forma:SolidPeso molecular:475.532PI3-Kinase α Inhibitor 2 (hydrochloride)
CAS:<p>PI3-Kinase α Inhibitor 2 (hydrochloride) is a PI3-Kinase α inhibitor.</p>Fórmula:C16H17Cl2N3O2SCor e Forma:SolidPeso molecular:386.3Simotinib hydrochloride
CAS:<p>Simotinib hydrochloride: selective oral EGFR inhibitor, IC50 19.9 nM, potent anticancer agent.</p>Fórmula:C25H27Cl2FN4O4Cor e Forma:SolidPeso molecular:537.41EGFR-IN-42
<p>EGFR-IN-42 (17b) is a potent EGFR inhibitor with nanomolar efficacy, merging tamoxifen/endoxifen and gefitinib, exhibiting enhanced anti-cancer action.</p>Fórmula:C49H53ClFN5O5Cor e Forma:SolidPeso molecular:846.436-Me-ATP
CAS:<p>6-Me-ATP, a modified ATP, binds well to GSK3 and donates phosphate for GSK3β phosphorylation.</p>Fórmula:C11H18N5O13P3Cor e Forma:SolidPeso molecular:521.212B-(SP)
CAS:<p>Selective phosphopeptide substrate for glycogen synthase kinase-3 (GSK-3)</p>Fórmula:C71H123N26O29PPureza:98%Cor e Forma:SolidPeso molecular:1835.87Istiratumab
CAS:<p>Istiratumab (M-6495) is a bispecific antibody against IGF-1R/ErbB3 for cancer research, promoting receptor degradation.</p>Cor e Forma:LiquidPhosphatidylinositol 4,5-bisphosphate
CAS:<p>Phosphatidylinositol 4,5-bisphosphate, a cell membrane phospholipid, is a PLC and PI3K substrate and a messenger.</p>Fórmula:C47H85O19P3Cor e Forma:SolidPeso molecular:1047.09AG-1478 hydrochloride
CAS:<p>AG1478 HCl is an epidermal growth factor receptor protein inhibitor.</p>Fórmula:C16H15Cl2N3O2Cor e Forma:SolidPeso molecular:352.21HER2-IN-14
CAS:<p>HER2-IN-14 (Compound 34) is a potent inhibitor of HER2, achieving an inhibitory concentration (IC50) of 18 nM.</p>Fórmula:C26H23ClF2N8O3Cor e Forma:SolidPeso molecular:568.96PI3Kγ inhibitor 5
CAS:<p>PI3Kγ inhibitor 5 is a potent inhibitor of phosphoinositide 3-kinase γ (PI3Kγ), exhibiting an exceptional IC50 value of 34 nM.</p>Fórmula:C28H32F2N6O4Cor e Forma:SolidPeso molecular:554.599(3S)-GSK-F1
CAS:<p>(3S)-GSK-F1 is a selective small molecule inhibitor of Type III Phosphatidylinositol 4‑Kinase Alpha (PI4KIIIα), pIC50=8.3.</p>Fórmula:C27H18F5N5O4SPureza:99.04%Cor e Forma:SoildPeso molecular:603.52DSPE-PEG2000-GE11
<p>DSPE-PEG2000-GE11 is a PEG compound composed of DSPE and an EGFR-targeting peptide (GE11). GE11 is applicable for cancer cells that overexpress EGFR. DSPE-PEG2000-GE11 is utilized in drug delivery.</p>Cor e Forma:Odour SolidQL-IX-55
CAS:<p>QL-IX-55 has a wide range of applications in life science related research.</p>Fórmula:C24H14F4N4OCor e Forma:SolidPeso molecular:450.39DP-C-4
<p>DP-C-4 is a Cereblon-based dual PROTAC for simultaneous degradation of EGFR and PARP[1].</p>Cor e Forma:LiquidOK2
<p>OK2, a specific inhibitor of the CCN2/EGFR interaction, effectively disrupts this interaction by binding to the CT domain of CCN2.</p>Fórmula:C42H62N14O9Pureza:98%Cor e Forma:SolidPeso molecular:907.03Duligotuzumab
CAS:<p>Duligotuzumab is a dual-targeting anti-EGFR/HER3 mAb that blocks signaling and induces ADCC for tumors with poor prognosis.</p>Pureza:95% - 95%Cor e Forma:LiquidAMX-818
<p>AMX-818 is a conditionally activated, masked T cell engager (TCE) that targets HER2. It demonstrates potent T cell cytotoxicity against HER2-positive tumor cell lines and can induce tumor regression in vivo. AMX-818 holds promise for research into HER2-positive solid tumors.</p>Cor e Forma:Odour LiquidCetuximab (PBS)
<p>Cetuximab (PBS) is a human IgG1 monoclonal antibody that inhibits the epidermal growth factor receptor (EGFR), with a dissociation constant (Kd) of 0.201 nM for EGFR as measured by the SPR method. It exhibits potent antitumor activity.</p>Cor e Forma:Odour LiquidCYH33
CAS:<p>CYH33: Oral PI3Kα inhibitor, IC50=5.9 nMα/598 nMβ/78.7 nMδ/225 nMγ; blocks Akt, ERK; causes G1 arrest in breast/lung cancer; effective on solid tumors.</p>Fórmula:C24H29F3N8O5SCor e Forma:SolidPeso molecular:598.6Depatuxizumab MMAF
<p>Depatuxizumab-MMAF, an antibody-drug conjugate (ADC), comprises an EGFR-targeted antibody linked to McMMAF and is utilized in glioblastoma research.</p>Cor e Forma:LiquidPeso molecular:148.24 kDaDSPE-PEG5000-GE11
<p>DSPE-PEG5000-GE11 is a PEG compound composed of DSPE and the EGFR-targeting peptide (GE11). GE11 is applicable for cancer cells with EGFR overexpression. DSPE-PEG5000-GE11 is utilized in drug delivery.</p>Cor e Forma:Odour SolidMS9427
CAS:<p>MS9427: PROTAC EGFR degrader, 7.1 nM (WT), 4.3 nM (L858R); targets mutant via UPS and autophagy; inhibits NSCLC cell growth; anticancer research.</p>Fórmula:C48H58ClFN8O12Cor e Forma:SolidPeso molecular:993.47EGFR T790M/L858R-IN-9
<p>EGFRT790M/L858R-IN-9 (Compound 8) is an inhibitor targeting the EGFR-L858R/T790M mutations. It effectively inhibits the phosphorylation of the EGFR-L858R/T790M mutant kinase, demonstrating an IC50 value of 0.0064 µM. Additionally, EGFRT790M/L858R-IN-9 can suppress the proliferation of non-small cell lung cancer (NSCLC) cells, making it useful for cancer research.</p>Fórmula:C26H27N7O3SCor e Forma:SolidPeso molecular:517.603HL-8
CAS:<p>HL-8, a PROTAC targeting PI3K, degrades it fully at 10 μM in 8h, useful in cancer research.</p>Fórmula:C57H59F2N11O9S2Cor e Forma:SolidPeso molecular:1144.27GSK3β/mTOR modulator 1
<p>GSK3β/mTOR modulator 1 (derivative 2) is an agent that modulates the GSK3β/mTOR signaling pathway. It is applicable in research related to acute lung injury (ALI) and inflammation.</p>Fórmula:C19H28O5Cor e Forma:SolidPeso molecular:336.19367Anti-ERBB3/HER3 (29Z6)
<p>Anti-ERBB3/HER3 (29Z6) is an antibody inhibitor targeting human ERBB3/HER3.</p>Cor e Forma:Odour LiquidEGFR-IN-22
CAS:<p>EGFR-IN-22: potent for EGFR (IC50: 4.91 nM) & L858R/T790M/C797S mutation (IC50: 0.54 nM).</p>Fórmula:C38H47BrFN10O2PCor e Forma:SolidPeso molecular:805.72JBJ-09-063 TFA
<p>JBJ-09-063 TFA, an EGFR inhibitor selective for EGFR mutations, IC50s: 0.147-0.396 nM, blocks EGFR/Akt/ERK signaling, for EGFR-mutant lung cancer research.</p>Fórmula:C33H30F4N4O5SCor e Forma:SolidPeso molecular:670.67Varlitinib
CAS:<p>Varlitinib (ASLAN001) is a potent, reversible, small molecule pan-EGFR inhibitor with IC50s of 7, 2, 4 nM for HER1, HER2 and HER4, respectively.</p>Fórmula:C22H19ClN6O2SPureza:99.7%Cor e Forma:SolidPeso molecular:466.94EGFR/VEGFR2-IN-5
<p>EGFR/VEGFR2-IN-5 (Compound 14) is an orally active dual inhibitor of EGFR and VEGFR2, exhibiting an IC50 value of 1.15 µM for VEGFR2 and 0.28 µM for EGFRT790M. This compound demonstrates significant anticancer activity.</p>Fórmula:C17H15N7O5SCor e Forma:SolidPeso molecular:429.41DS06652923
<p>DS06652923 is an orally active inhibitor targeting EGFR triple mutations. It exhibits growth-inhibitory effects on Ba/F3EGFRdel19/T90M/C795S cells, with a GI50 value of 9.4 nM. Additionally, DS06652923 induces tumor regression in the Ba/F3 syngeneic transplantation model.</p>Cor e Forma:Odour SolidDA-143
<p>DA-143 is a selective inhibitor of DNA-PKcs (IC50: 2.5 nM), demonstrating disparate inhibitory effects on mTOR, PI3KΔ, and ATM, with IC50 values of 280 nM, 106 nM, and 6,594 nM, respectively. This compound effectively blocks the phosphorylation of DNA-PKcs substrates and enhances the sensitivity of cancer cells to doxorubicin.</p>Cor e Forma:Odour SolidPROTAC EGFR degrader 2
<p>Potent PROTAC EGFR degrader 2; IC50: 4.0 nM, DC50: 36.51 nM; inhibits cell growth; for NTR-responsive synthesis.</p>Fórmula:C58H72ClFN12O8SCor e Forma:SolidPeso molecular:1151.78ALKBH1-IN-3
<p>ALKBH1-IN-3 is an effective inhibitor of the DNA N6-methyladenosine (6mA) demethylase ALKBH1. This compound enhances the abundance of 6mA in gastric cancer cell lines HGC27 and AGS, simultaneously inhibiting cell viability and upregulating the AMP-activated protein kinase (AMPK) signaling pathway. ALKBH1-IN-3 holds potential for use in cancer research, including studies on gastric cancer.</p>Cor e Forma:Odour SolidARRY-380 (analog )
CAS:<p>ARRY-380 analog (HER2-Inhibitor-1) is a potent and selective HER2 inhibitor.</p>Fórmula:C29H27N7O4SPureza:99.82%Cor e Forma:SolidPeso molecular:569.63FAP-PI3KI1
CAS:<p>FAP-PI3KI1: A FAP-targeted PI3K inhibitor reducing collagen synthesis in human IPF cells.</p>Fórmula:C52H48F4N10O12S3Cor e Forma:SolidPeso molecular:1177.19EGFR-IN-124
<p>EGFR-IN-124 (compound 10A) is an EGFR inhibitor with an IC50 value of 0.54 μM, utilized in cancer research.</p>Cor e Forma:Odour SolidEGFR-IN-127
<p>EGFR-IN-127 is an ATP-competitive inhibitor targeting EGFR, with IC50 values of 136.3 nM for EGFRdel19 and 161.2 nM for EGFRdel19/T790M/C797S. This compound holds potential for the study of non-small cell lung cancer (NSCLC).</p>Cor e Forma:Odour SolidIC 86621
CAS:<p>IC 86621: DNA-PK ATP-competitive inhibitor, IC50 120 nM, enhances DSB antitumor effects, EC50 68 µM for repair.</p>Fórmula:C12H15NO3Pureza:99.68%Cor e Forma:SolidPeso molecular:221.25GSK-3β inhibitor 21
<p>GSK-3β Inhibitor21 (compound 44) is an ATP-competitive inhibitor of GSK-3β with an IC50 value of 6.06 µM, characterized by its ability to inhibit tau phosphorylation and prevent amyloid protein aggregation. This compound is utilized in the research of Alzheimer's disease.</p>Cor e Forma:Odour SolidCetuximab MMAE
<p>Cetuximab-MMAE, an antibody-drug conjugate (ADC), combines an EGFR-targeting antibody with Monomethyl auristatin E (MMAE) to investigate colorectal and head and neck cancers.</p>Cor e Forma:LiquidPeso molecular:150 kDaUmbralisib R-enantiomer
CAS:<p>Umbralisib R-enantiomer (RP5264 R-enantiomer) is a delta inhibitor of PI3K and a less active enantiomer of TGR-1202.</p>Fórmula:C31H24F3N5O3Pureza:97.34%Cor e Forma:SolidPeso molecular:571.55GSK-3β inhibitor 24
<p>GSK-3β inhibitor24 (Compound 41) is a potent GSK-3β inhibitor with an IC50 of 0.22 nM. It increases GSK-3β phosphorylation at the Ser9 site in a dose-dependent manner and inhibits tau protein hyperphosphorylation by reducing the abundance of p-tau-Ser396. The compound upregulates β-catenin and neurogenesis-related markers (GAP43 and MAP-2), demonstrating significant anti-Alzheimer's disease (AD) activity.</p>Fórmula:C26H18N4O3Cor e Forma:SolidPeso molecular:434.446HER2/neu (654-662) GP2
CAS:<p>Phage display selected Affibody ligands for HER2/neu from a protein library based on a 58-residue Staphylococcal protein A Z domain.</p>Fórmula:C42H77N9O11Pureza:98%Cor e Forma:SolidPeso molecular:884.11EGFR/PI3Kα-IN-1
<p>EGFR/PI3Kα-IN-1 (compound 30k), a dual EGFR/PI3Kα inhibitor, exhibits potent activity with IC 50 values of 3.6 nM (EGFRL858R/T790M) and 30 nM (PI3Kα). It effectively inhibits tumor cell proliferation and demonstrates significant anticancer activity.</p>Fórmula:C50H49N11O5SCor e Forma:SolidPeso molecular:916.06GSK-3β inhibitor 23
<p>GSK-3β inhibitor23 (Compound 11726169) is an inhibitor of glycogen synthase kinase 3 (GSK-3), effectively inhibiting GSK-3β and GSK-3α with IC50 values of 12.1 nM and 18.8 nM, respectively. It demonstrates antiviral activity against HIV1 and exhibits good metabolic stability in mouse and human liver microsomes and plasma, although it has poor permeability in Caco-2 cells, indicating potentially low oral bioavailability.</p>Fórmula:C18H13Cl2N5O2SCor e Forma:SolidPeso molecular:434.299Tephrosin
CAS:<p>Tephrosin induces degradation of of EGFR and ErbB2 by inducing internalization of the receptors, has potent antitumor activities.</p>Fórmula:C23H22O7Pureza:98%Cor e Forma:SolidPeso molecular:410.42MC-Val-Cit-PAB-Amide-TLR7 agonist 4 Conjugate
CAS:<p>MC-Val-Cit-PAB-Amide-TLR7 agonist 4 Conjugate is a conjugate formed by linking MC-Val-Cit-PAB-Amide and TLR7 agonist 4, useful for cancer research.</p>Fórmula:C52H72N12O11Pureza:97.70%Cor e Forma:SolidPeso molecular:1041.2IBI-334
<p>IBI-334 is a bispecific antibody targeting both B7-H3 and EGFR. It features an EGFR arm responsible for signal blocking, connected to a modified B7-H3 arm that ensures optimal affinity and binding. The antibody is afucosylated to enhance its antibody-dependent cellular cytotoxicity (ADCC) effects. IBI-334 is widely applicable in EGFR-driven solid tumors.</p>Cor e Forma:Odour LiquidGSK-3β inhibitor 19
<p>GSK-3β Inhibitor 19 (compound 36) is an inhibitor of GSK-3β with an IC50 value of 70 nM. It is applicable in research related to anti-inflammatory and Alzheimer's disease.</p>Fórmula:C15H12N4O2SCor e Forma:SolidPeso molecular:312.35YH32367
<p>YH32367 (ABL105) is a bispecific antibody targeting HER2 and 4-1BB. It induces the secretion of IFN-γ, resulting in the death of tumor cells when co-cultured with hPBMC and HER2-expressing tumor cells. YH32367 demonstrates notable antitumor activity.</p>Cor e Forma:Odour LiquidTimigutuzumab
CAS:<p>Timigutuzumab (GEXMab73) is a humanized monoclonal antibody designed to target ErbB2, showing potential application in cancer research [1].</p>Cor e Forma:LiquidAnticancer agent 271
<p>Anticanceragent 271 (compound 5C) exhibits antiproliferative activity against lung cancer (A549), colon cancer (Caco-2) cell lines, and human lung fibroblasts (WI38), with an IC50 value of 9.18 μM for A549 cells. This compound can downregulate PI3K and mTOR gene expression and is applicable in cancer research.</p>Cor e Forma:Odour SolidWAY-270360
CAS:<p>WAY-270360 (N-[4-(1H-benzimidazol-2-yl)phenyl]-2,4-dimethoxybenzamide) is a sirtuin modulator and an epidermal growth factor receptor (EGFR) inhibitor.</p>Fórmula:C22H19N3O3Pureza:98.05%Cor e Forma:SolidPeso molecular:373.4DSPE-PEG1000-GE11
<p>DSPE-PEG1000-GE11 is a PEG compound made up of DSPE and an EGFR-targeting peptide (GE11). GE11 is applicable for cancer cells overexpressing EGFR. DSPE-PEG1000-GE11 serves a role in drug delivery.</p>Cor e Forma:Odour SolidPX-866-17OH
CAS:<p>PX-866-17OH can be used in related research in the field of life sciences. Its product number is T36312 and CAS number is 1012327-63-7.</p>Fórmula:C29H37NO8Cor e Forma:SolidPeso molecular:527.61IHMT-PI3K-315
<p>IHMT-PI3K-315 (20e) serves as a potent, selective inhibitor of PI3Kγ/δ, exhibiting IC 50 values of 4.0 nM for PI3Kγ and 9.1 nM for PI3Kδ. Additionally, it demonstrates antitumor activity.</p>Fórmula:C22H20F2N6O4Cor e Forma:SolidPeso molecular:470.43Varlitinib Tosylate
CAS:<p>Varlitinib Tosylate is a selective and potent inhibitor of ErbB1(EGFR) and ErbB2(HER2).</p>Fórmula:C36H35ClN6O8S3Pureza:98%Cor e Forma:SolidPeso molecular:811.34RMC-4529
CAS:<p>RMC-4529 is a chemical compound that demonstrates potent inhibition, with an IC50 value of 1.0 nM, against p-4E-BP1-(T37/46) in mTOR kinase cellular assays.</p>Fórmula:C90H139N13O23Cor e Forma:SolidPeso molecular:1771.17Lyso-Monosialoganglioside GM3
CAS:<p>Lyso-Monosialoganglioside GM3 (Lyso-GM3) is an analog of Ganglioside GM3 with antitumor properties. It inhibits the increase in EGFR kinase activity induced by EGF in A431 epithelial cancer cells.</p>Fórmula:C41H74N2O20Cor e Forma:SolidPeso molecular:915.028GSK2292767 FA
<p>GSK2292767 FA: potent PI3Kδ inhibitor, pIC50=10.1, 500x selectivity, for respiratory research.</p>Fórmula:C25H30N6O7SPureza:99.52%Cor e Forma:SoildPeso molecular:558.61AZ14240475
<p>AZ14240475 is a potent, selective, brain-penetrant inhibitor of EGFREx20Ins mutants (EGFREx20Ins mutants) with a pIC50 of 7.6, playing a significant role in cancer research.</p>Fórmula:C23H15ClF2N6O2Cor e Forma:SolidPeso molecular:480.854EGFR-IN-148
<p>EGFR-IN-148 (compound 8c) is a potent EGFR inhibitor with an IC50 of 0.161 μM. It induces G1/S phase arrest and significantly enhances apoptosis in HepG2 cells.</p>Fórmula:C17H16N4O4SCor e Forma:SolidPeso molecular:372.398Inetetamab
<p>Inetetamab is a recombinant humanized antibody targeting HER2 receptor domain IV, with anticancer activity, inducing pyroptosis in lung adenocarcinoma.</p>Pureza:96.54% (SEC-HPLC) - 96.54% (SEC-HPLC)Cor e Forma:Odour LiquidPI3K-IN-22
CAS:<p>PI3K-IN-22 is a dual kinase inhibitor of PI3Kα and mTOR, with IC50s of 0.9 and 0.6 nM respectively. PI3K-IN-22 could be used in cancer.</p>Fórmula:C31H35F3N8O3Cor e Forma:SolidPeso molecular:624.66GW 583340
CAS:<p>GW 583340 is a potent and selective dual inhibitor of EGFR/ErbB2 tyrosine kinase with the advantage of oral dosability and antitumor effects.</p>Fórmula:C28H25ClFN5O3S2Pureza:98.68%Cor e Forma:SoildPeso molecular:598.11PI3Kα-IN-25
<p>PI3Kα-IN-25 (Compound Djh1) is a selective inhibitor of PI3Kα, suitable for research in triple-negative breast cancer.</p>Fórmula:C21H19ClN4O4Cor e Forma:SolidPeso molecular:426.853mTOR inhibitor 9f
CAS:<p>mTOR inhibitor 9f is a selective mTOR inhibitor with IC50 of 1.25nM and 82nM for mTOR and PI3Kα, respectively.</p>Fórmula:C25H23N5O2SPureza:99.18%Cor e Forma:SoildPeso molecular:457.55CZY43
<p>CZY43 is an HER3 degrader that effectively induces degradation of HER3 in breast cancer SKBR3 cells in a dose- and time-dependent manner. It efficiently inhibits HER3-dependent signaling and cancer cell growth, outperforming Bosutinib.</p>Fórmula:C42H53Cl2N5O3Cor e Forma:SolidPeso molecular:746.808RMC-4627
CAS:<p>RMC-4627 is a selective mTORC1 inhibitor that activates 4EBP1 and inhibits tumor growth.</p>Fórmula:C93H141N11O23Cor e Forma:SolidPeso molecular:1781.17
